Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Italian Multicenter Study of FOLFOXIRI vs Gemcitabine as Adjuvant Therapy for Resected Pancreatic Cancer
2013-003080-59Phase 3Active
- Sponsor
- Azienda Ospedaliero-Universitaria Pisana
- Start
- Aug 2013
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of gemcitabine, fluorouracil, oxaliplatin, irinotecan and levoleucovorin in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Azienda Ospedaliero-Universitaria Pisana. Primary endpoint: Disease-free survival. Started Aug 2013; status: active.
02
Drugs
gemcitabinefluorouraciloxaliplatinirinotecanlevoleucovorin
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2013-003080-59.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003080-59.